New nitrosamine reference standards unveiled by Indian Pharmacopoeia
In a landmark announcement during the Kolkata workshop, the Indian Pharmacopoeia Commission released seven nitrosamine impurity reference standards for the first time. The standards, which include NDMA, NDEA, NEIPA, NDBA, NMPA, NDIPA and NAMB, provide calibrated material that analytical labs can use to verify the presence and concentration of these carcinogenic compounds.
Nitrosamines can arise when amine‑containing substances react with nitrites under certain manufacturing or storage conditions. Their inadvertent formation has been linked to several high‑profile drug recalls worldwide. By supplying domestically produced reference standards, the IPC aims to boost analytical capability, reduce reliance on costly imports and align Indian testing practices with international guidelines such as those of the ICH.
Regulators expect that the availability of these standards will accelerate the implementation of stricter limits for nitrosamines in medicines that treat hypertension, gastrointestinal disorders, diabetes and tuberculosis. Accurate measurement will also support manufacturers in demonstrating compliance during product dossier submissions and routine market surveillance.
The IPC Secretary‑Scientific Director emphasized that the new standards are a critical component of the IPC 2026 roadmap, which seeks to modernise the Indian pharmacopoeial framework and enhance public health protection.